Safety of biologic therapies - An update

被引：0
|
作者：
Keystone, EC
机构：
[1] Mt Sinai Hosp, Rebecca MacDonald Ctr Arthrit & Autoimmune Dis, Div Adv Therapeut, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Div Adv Therapeut, Toronto, ON, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2005年 / 32卷
关键词：
biologic therapies; rheumatoid arthritis; safety; clinical trials;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Tumor necrosis factor (TNF) antagonists have set a new therapeutic standard for rheumatoid arthritis (RA). Agents including infliximab, etanercept, and adalimumab have demonstrated substantial improvement in signs and symptoms, disability, and quality of life, while significantly inhibiting joint damage in early and long-standing RA. Safety issues in concert with efficacy determine risk/benefit ratio and hence a position in the therapeutic algorithm. This brief review focuses on infection, congestive heart, and malignancy.
引用
收藏
页码：8 / 12
页数：5
相关论文
共 50 条
  • [21] An update on the use of biologic therapies in the management of uveitis in Behcet's disease: a comprehensive review
    McNally, Thomas W.
    Damato, Erika M.
    Murray, Philip I.
    Denniston, Alastair K.
    Barry, Robert J.
    ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
  • [22] Overview of safety of non-biologic and biologic DMARDs
    Ruderman, Eric M.
    RHEUMATOLOGY, 2012, 51 : 37 - 43
  • [23] The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis
    Wang, Dashan
    Li, Yan
    Liu, Yuan
    Shi, Guixiu
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2014, 15 (06) : 542 - 548
  • [24] Biologic therapies and pregnancy: the story so far
    Hyrich, Kimme L.
    Verstappen, Suzanne M. M.
    RHEUMATOLOGY, 2014, 53 (08) : 1377 - 1385
  • [25] Biologic Therapies in Primary Sjogren's Syndrome
    Bowman, S. J.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2012, 13 (10) : 1997 - 2008
  • [26] Biologic therapies for the treatment of systemic lupus erythematosus
    Park, Sung-Hoon
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (02): : 109 - 115
  • [27] Predictors of response to biologic therapies in rheumatoid arthritis
    不详
    REUMATOLOGIA CLINICA, 2011, 7 (02): : 141 - 144
  • [28] Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety
    Favalli, E. G.
    Caporali, R.
    Sinigaglia, L.
    Pipitone, N.
    Miniati, I.
    Montecucco, C.
    Matucci-Cerinic, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (03) : S15 - S27
  • [29] An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine
    Khoury, Rita
    Rajamanickam, Jayashree
    Grossberg, George T.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2018, 9 (03) : 171 - 178
  • [30] Biologic therapies in the treatment of sarcoidosis
    Saketkoo, Lesley Ann
    Baughman, Robert P.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (08) : 817 - 825
12345